Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 2, 2010, Pages 118-124

  Sugano, Kiyohiko ^a   Kataoka, Makoto ^b   da Costa Mathews, Claudia ^a   Yamashita, Shinji ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b SETSUNAN UNIVERSITY   (Japan)

Author keywords

Bile micelles; Dissolution; Food effect; Free fraction; Oral absorption; Permeability; Simulation; Solubility; Unstirred water layer

Indexed keywords

ATOVAQUONE; CHLOROTHIAZIDE; DANAZOL; GRISEOFULVIN; IRBESARTAN; IVERMECTIN; PHENYTOIN; PRANLUKAST;

ARTICLE; BILE COMPOSITION; CONCENTRATION (PARAMETERS); CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; FOOD; FOOD DRUG INTERACTION; INTESTINE EPITHELIUM; INTESTINE FLUID; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MICELLE; NANOEMULSION; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; BILE; CELL MEMBRANE PERMEABILITY; DANAZOL; FOOD; INTESTINAL ABSORPTION; MICELLES; MODELS, BIOLOGICAL; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; SOLUBILITY;

EID: 77952236114     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.03.011     Document Type: Article

References (67)

1. Ahmed I.S., Aboul-Einien M.H., Mohamed O.H., Farid S.F. Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: a single-dose, randomized, open-label, six-period, crossover study in healthy adult volunteers in the fasted and fed states. Eur. J. Pharm. Sci. 2008, 35:219-225.
2. Amidon G.E., Higuchi W.I., Ho N.F.H. Theoretical and experimental studies of transport of micelle-solubilized solutes. J. Pharm. Sci. 1982, 71:77-84.
3. Avdeef A. Absorption and Drug Development. 2003, Wiley-Interscience.
4. Bakatselou V., Oppenheim R.C., Dressman J.B. Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm. Res. 1991, 8:1461-1469.
5. Brewster M.E., Noppe M., Peeters J., Loftsson T. Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int. J. Pharm. 2007, 342:250-253.
6. DeSesso J.M., Jacobson C.F. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. 2001, 39:209-228.
7. DeSesso J.M., Williams A.L. Contrasting the gastrointestinal tracts of mammals: factors that influence absorption. Annu. Rep. Med. Chem. 2008, 43:353-371.
8. Diakidou A., Vertzoni M., Goumas K., Soederlind E., Abrahamsson B., Dressman J., Reppas C. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm. Res. 2009, 26:2141-2151.
9. Dongowski G., Fritzsch B., Giessler J., Haertl A., Kuhlmann O., Neubert R.H.H. The influence of bile salts and mixed micelles on the pharmacokinetics of quinine in rabbits. Eur. J. Pharm. Biopharm. 2005, 60:147-151.
10. Dressman J.B., Fleisher D., Amidon G.L. Physicochemical model for dose-dependent drug absorption. J. Pharm. Sci. 1984, 73:1274-1279.
11. Fadda H.M., McConnell E.L., Short M.D., Basit A.W. Meal-induced acceleration of tablet transit through the human small intestine. Pharm. Res. 2009, 26:356-360.
12. Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15:698-705.
13. Glomme A., März J., Dressman J. Predicting the intestinal solubility of poorly soluble drugs. Pharmacokinetic Profiling in Drug Research 2006, 259-280. Wiley-VCH, Zurich. B. Testa, S. Krämer, H. Wunderli-Allenspach, G. Folkers (Eds.).
14. Gu C.-H., Li H., Levons J., Lentz K., Gandhi R.B., Raghavan K., Smith R.L. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm. Res. 2007, 24:1118-1130.
15. Guzzo C.A., Furtek C.I., Porras A.G., Chen C., Tipping R., Clineschmidt C.M., Sciberras D.G., Hsieh J.Y.K., Lasseter K.C. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J. Clin. Pharmacol. 2002, 42:1122-1133.
16. Hamaguchi T, Shinkuma D., Irie T., Yamanaka Y., Morita Y., Iwamoto B., Miyoshi K., Mizuno N. Effect of a high-fat meal on the bioavailability of phenytoin in a commercial powder with a large particle size. Int. J. Clin. Pharmacol. Ther. Toxicol. 1993, 31:326-330.
17. Hsu F.H., Prueksaritanont T., Lee M.G., Chiou W.L. The phenomenon and cause of the dose-dependent oral absorption of chlorothiazide in rats: extrapolation to human data based on the body surface area concept. J. Pharmacokinet. Biopharm. 1987, 15:369-386.
18. Ingels F., Beck B., Oth M., Augustijns P. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int. J. Pharm. 2004, 274:221-232.
19. Irbesartan, 2009. Irbesartan Interview form. ver. 3.
20. Kataoka M., Masaoka Y., Sakuma S., Yamashita S. Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system. J. Pharm. Sci. 2006, 95:2051-2061.
21. Lennernaes H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 2007, 37:1015-1051.
22. Lennernaes H., Regaardh C.G. Evidence for an interaction between the b-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm. Res. 1993, 10:879-883.
23. Lennernäs H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metab. 2007, 8:645-657.
24. Lentz K.A. Current methods for predicting human food effect. AAPS J. 2008, 10:282-288.
25. Li C.-Y., Zimmerman C.L., Wiedmann T.S. Diffusivity of bile salt/phospholipid aggregates in mucin. Pharm. Res. 1996, 13:535-541.
26. Madan J., Chawla G., Arora V., Malik R., Bansal A.K. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J. 2005, 7:E224-E230.
27. Marasanapalle V.P., Crison J.R., Ma J., Li X., Jasti B.R. Investigation of some factors contributing to negative food effects. Biopharm. Drug Dispos. 2009, 30:71-80.
28. McConnell E.L., Fadda H.M., Basit A.W. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 2008, 364:213-226.
29. McGinnity D.F., Collington J., Austin R.P., Riley R.J. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs. Curr. Drug Metab. 2007, 8:463-479.
30. Mizuta H., Kawazoe Y., Haga K., Ogawa K. Effects of meals on gastric emptying and small intestinal transit times of a suspension in the beagle dog assessed using acetaminophen and salicylazosulfapyridine as markers. Chem. Pharm. Bull. 1990, 38:2224-2227.
31. Nakajima M., Kanamaru M., Umematsu T., Tsubokura S. A phase I clinical study of a leukotriene C4, D4 and E4 receptor antagonist; ONO-1078 in healthy volunteers. Rynsho iyaku 1993, 9(Suppl. 1).
32. Obata K., Sugano K., Saitoh R., Higashida A., Nabuchi Y., Machida M., Aso Y. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int. J. Pharm. 2005, 293:183-192.
33. Oh D.M., Curl R.L., Amidon G.L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res. 1993, 10:264-270.
34. Okazaki A., Mano T., Sugano K. Theoretical dissolution model of poly-disperse drug particles in biorelevant media. J. Pharm. Sci. Technol. Jpn. (Meet. Abstract Poster) 2007, 67.
35. Okazaki A., Mano T., Sugano K. Theoretical dissolution model of poly-disperse drug particles in biorelevant media. J. Pharm. Sci. 2008, 97:1843-1852.
36. Oliver R.E., Jones A.F., Rowland M. What surface of the intestinal epithelium is effectively available to permeating drugs?. J. Pharm. Sci. 1998, 87:634-639.
37. Persson E.M., Nordgren A., Forsell P., Knutson L., Oehgren C., Forssen S., Lennernaes H., Abrahamsson B. Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. Eur. J. Pharm. Sci. 2008, 34:22-29.
38. Poelma F.G.J., Breaes R., Tukker J.J. Intestinal absorption of drugs. III. The influence of taurocholate on the disappearance kinetics of hydrophilic and lipophilic drugs from the small intestine of the rat. Pharm. Res. 1990, 7:392-397.
39. Poelma F.G.J., Breas R., Tukker J.J., Crommelin D.J.A. Intestinal absorption of drugs. The influence of mixed micelles on the disappearance kinetics of drugs from the small intestine of the rat. J. Pharm. Pharmacol. 1991, 43:317-324.
40. Rolan P.E., Mercer A.J., Weatherley B.C., Holdich T., Meire H., Peck R.W., Ridout G., Posner J. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br. J. Clin. Pharmacol. 1994, 37:13-20.
41. Saitoh R., Sugano K., Takata N., Tachibana T., Higashida A., Nabuchi Y., Aso Y. Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm. Res. 2004, 21:749.
42. Schiller C., Frohlich C.P., Giessmann T., Siegmund W., Monnikes H., Hosten N., Weitschies W. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 2005, 22:971-979.
43. Singh B.N. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. 1999, 37:213-255.
44. Singh B.N. A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio, and partition coefficient (logP) for orally active drugs administered as immediate-release formulations. Drug Dev. Res. 2005, 65:55-75.
45. Sugano K. Estimation of effective intestinal membrane permeability considering bile micelle solubilisation. Int. J. Pharm. 2009, 368:116-122.
46. Sugano K. Fraction of dose absorbed calculation: comparison between analytical solution based on one compartment steady state approximation and dynamic seven compartment model. CBI J. 2009, 9:75-93.
47. Sugano K. Introduction to computational oral absorption simulation. Exp. Opin. Drug Metab. Toxicol. 2009, 5:259-293.
48. Sugano K. Oral absorption simulation for poor solubility compounds. Chem. Biodivers. 2009, 6(11):2014-2029.
49. Sugano K. Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug like molecule population. Int. J. Pharm. 2009, 373(1-2):55-61.
50. Sugano K., Cucurull-Sanchez L., Bennett J. Membrane permeability-measurement and prediction in drug discovery. Hit to Lead Optimization 2009, 117-143. WIEY-VCH, Weinheim. B. Faller, L. Urban (Eds.).
51. Sugano K., Nabuchi Y., Machida M., Aso Y. Prediction of human intestinal permeability using artificial membrane permeability. Int. J. Pharm. 2003, 257:245-251.
52. Sugano K., Obata K., Saitoh R., Higashida A., Hamada H. Processing of biopharmaceutical profiling data in drug discovery. Pharmacokinetic Profiling in Drug Research 2006, 441-458. Wiley-VCH, Zurich. B. Testa, S. Krämer, H. Wunderli-Allenspach, G. Folkers (Eds.).
53. Sugano K., Okazaki A., Sugimoto S., Tavornvipas S., Omura A., Mano T. Solubility and dissolution profile assessment in drug discovery. Drug Metab. Pharmacokinet. 2007, 22:225-254.
54. Sugano K., Takata N., Machida M., Saitoh K., Terada K. Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. Int. J. Pharm. 2002, 241:241-251.
55. Sunesen V.H., Vedelsdal R., Kristensen H.G., Christrup L., Muellertz A. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur. J. Pharm. Sci. 2005, 24:297-303.
56. Takano R., Furumoto K., Shiraki K., Takata N., Hayashi Y., Aso Y., Yamashita S. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm. Res. 2008, 25:2334-2344.
57. Takano R., Sugano K., Higashida A., Hayashi Y., Machida M., Aso Y., Yamashita S. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 2006, 23:1144-1156.
58. Thombre A.G. Assessment of the feasibility of oral controlled release in an exploratory development setting. Drug Discov. Today 2005, 10:1159-1166.
59. Vachharajani N.N., Shyu W.C., Mantha S., Park J.S., Greene D.S., Barbhaiya R.H. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J. Clin. Pharmacol. 1998, 38:433-436.
60. Vertzoni M., Fotaki N., Kostewicz E., Stippler E., Leuner C., Nicolaides E., Dressman J., Reppas C. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 2004, 56:453-462.
61. Wu C.-Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005, 22:11-23.
62. Yamaguchi T., Ikeda C., Sekine Y. Intestinal absorption of a b-adrenergic blocking agent nadolol. I. Comparison of absorption behavior of nadolol with those of other b-blocking agents in rats. Chem. Pharm. Bull. 1986, 34:3362-3369.
63. Yamaguchi T., Ikeda C., Sekine Y. Intestinal absorption of a b-adrenergic blocking agent nadolol. II. Mechanism of the inhibitory effect on the intestinal absorption of nadolol by sodium cholate in rats. Chem. Pharm. Bull. 1986, 34:3836-3843.
64. Yamaguchi T., Oida T., Ikeda C., Sekine Y. Intestinal absorption of a b-adrenergic blocking agent nadolol. III. Nuclear magnetic resonance spectroscopic study on nadolol-sodium cholate micellar complex and intestinal absorption of nadolol derivatives in rats. Chem. Pharm. Bull. 1986, 34:4259-4264.
65. Yamashita S., Furubayashi T., Kataoka M., Sakane T., Sezaki H., Tokuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 2000, 10:195-204.
66. Yu L.X. An integrated model for determining causes of poor oral drug absorption. Pharm. Res. 1999, 16:1883-1887.
67. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M.-L.Lee, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 2002, 19:921-925.